Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that since the company does not generate any sales from the facility, and approval of the 18 ANDAs (Abbreviated New Drug Application) were not expected until FY13, FY12 margins will remain intact.
first published: Jul 6, 2011 02:33 pm
A collection of the most-viewed Moneycontrol videos.
Live: Davos 2026 | Day 1 Highlights of World Economic Forum with Top Global Voices
Live: Nifty below 25,600 as heavyweights weigh, majority sectors in red | Closing Bell
Live: Can Nifty breach 25,900 after RIL, HDFC Bank Q3 results? | Opening Bell
Davos 2026: AI Will Consume Massive Energy! WEF’s Roberto Bocca Urges National Energy Security
